Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View Details•Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia®developed by Bio-Thera and to be marketed by STADA•Recommendation from EMA’s CHMP committee is based on a robust analytical, non-clinical and clinica...
Guangzhou, China; November 10, 2025: Bio-TheraSolutions (688177:SH; “Bio-Thera”), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and biosimilars, today announcedthat it has entered into an exclusive commerci...
GUANGZHOU,China - Bio-Thera Solutions (688177.SH), a commercial-stage biopharmaceutical companydeveloping innovative therapies and biosimilars, announced that its partner, HikmaPharmaceuticals USA Inc. officially launched STARJEMZA® (ustekinumab-hmny...
